Moore Capital Management LP Sells 40,000 Shares of AbbVie Inc. $ABBV

Key Points

• Moore Capital Management cut its position in AbbVie by 40% in Q3, selling 40,000 shares and now holds 60,000 shares valued at about $13.89 million.
• Company insiders also sold significant stock: EVP Perry C. Siatis sold 22,381 shares (reducing his stake ~37%) and SVP David Ryan Purdue sold 5,230 shares (reducing his stake ~66%).
• Analysts remain largely positive with a consensus "Moderate Buy" and average price target of $253.15; AbbVie beat Q results (EPS $2.71 vs. $2.65), set FY2026 guidance of 14.37–14.57 EPS, and announced a $1.73 quarterly dividend (3.1% yield).

Moore Capital Management LP reduced its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 40.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,000 shares of the company's stock after selling 40,000 shares during the period. Moore Capital Management LP's holdings in AbbVie were worth $13,892,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of ABBV. Ellenbecker Investment Group boosted its stake in AbbVie by 0.8% in the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company's stock valued at $1,235,000 after buying an additional 44 shares in the last quarter. Security National Bank of Sioux City Iowa IA grew its position in AbbVie by 0.3% in the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company's stock valued at $3,562,000 after acquiring an additional 45 shares during the period. Matthew Goff Investment Advisor LLC raised its stake in AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company's stock worth $4,066,000 after acquiring an additional 45 shares in the last quarter. Centennial Wealth Advisory LLC lifted its holdings in shares of AbbVie by 2.2% during the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company's stock valued at $484,000 after acquiring an additional 45 shares during the period. Finally, Willner & Heller LLC lifted its holdings in shares of AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company's stock valued at $1,759,000 after acquiring an additional 46 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.08% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Royal Bank Of Canada initiated coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 target price on the stock. BMO Capital Markets reissued an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Wall Street Zen upgraded shares of AbbVie from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 28th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research note on Tuesday, January 20th. Finally, Morgan Stanley upped their price objective on shares of AbbVie from $269.00 to $270.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, AbbVie currently has a consensus rating of "Moderate Buy" and an average price target of $253.15.

AbbVie Trading Up 0.8%

AbbVie stock opened at $221.54 on Tuesday. The firm has a market capitalization of $391.72 billion, a P/E ratio of 93.87, a PEG ratio of 0.76 and a beta of 0.34. The business has a 50-day moving average of $224.35 and a 200-day moving average of $224.89. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period last year, the company posted $2.16 EPS. AbbVie's revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.1%. AbbVie's dividend payout ratio (DPR) is 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.